Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Lisa Golden"'
Autor:
Johanna Bendell, Cathy Eng, Aimee Bence Lin, Richard Beckmann, Sameera Wijayawardana, Ricardo Martinez, Wei Zhang, Lisa Golden, Jeffrey Infante, Funda Meric-Bernstam, Suzanne Jones, William N. William, Howard A. Burris, Stefan C. Grant, Manish Patel, Kathleen Moore, David S. Hong
Purpose: Prexasertib, a checkpoint kinase 1 inhibitor, demonstrated single-agent activity in patients with advanced squamous cell carcinoma (SCC) in the dose-escalation portion of a phase I study (NCT01115790). Monotherapy prexasertib was further eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3def8fc747f50b3c45f3e858cb77f444
https://doi.org/10.1158/1078-0432.c.6527487
https://doi.org/10.1158/1078-0432.c.6527487
Autor:
Johanna Bendell, Cathy Eng, Aimee Bence Lin, Richard Beckmann, Sameera Wijayawardana, Ricardo Martinez, Wei Zhang, Lisa Golden, Jeffrey Infante, Funda Meric-Bernstam, Suzanne Jones, William N. William, Howard A. Burris, Stefan C. Grant, Manish Patel, Kathleen Moore, David S. Hong
Supplementary Table S1. JTJA Study Dose Expansion Cohorts; Supplementary Table S2. Baseline Disease Classifications of SCCHN Patients Supplementary Table S3. Treatment-Emergent Adverse Events Related to Study Treatment in >10% of Patients with Any Tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f3dc0ee5f74c72052eb96db9362bb74
https://doi.org/10.1158/1078-0432.22470258.v1
https://doi.org/10.1158/1078-0432.22470258.v1
Autor:
Janice MacLeod, LaurieAnn Scher, Patty Scalzo, Anastasia Albanese-O'Neill, Deborah Greenwood, Diana Isaacs, Megan S. O’Neill, Lisa Golden
Publikováno v:
ADCES in Practice. 9:34-41
Publikováno v:
ADCES in Practice. 9:12-17
Autor:
Amie DuBois, Tomás J. Aragón, Susan S. Philip, Lisa Golden, Juliet Stoltey, Hyman M. Scott, Janice K. Louie
Publikováno v:
Journal of the American Geriatrics Society
Autor:
Richard P. Beckmann, Cathy Eng, David S. Hong, Howard A. Burris, Ricardo Martinez, Sameera R. Wijayawardana, Stefan C. Grant, Kathleen N. Moore, William N. William, Suzanne F. Jones, Funda Meric-Bernstam, Wei Zhang, Jeffrey R. Infante, Lisa Golden, Johanna C. Bendell, Manish R. Patel, Aimee Bence Lin
Publikováno v:
Clinical Cancer Research. 24:3263-3272
Purpose: Prexasertib, a checkpoint kinase 1 inhibitor, demonstrated single-agent activity in patients with advanced squamous cell carcinoma (SCC) in the dose-escalation portion of a phase I study (NCT01115790). Monotherapy prexasertib was further eva
Autor:
Matthew Powell, Ignace Vergote, Daphne L. Farrington, Christine M. Lee, Katherine M Bell-McGuinn, Jalid Sehouli, Robert Bell, Kathleen N. Moore, Florian Heitz, Michael Teneriello, Paul Buderath, Celine Pitou, Wei Zhang, Robert M. Campbell, Robert M. Wenham, Lisa Golden, Anne Hamilton, James Fiorica
Publikováno v:
Gynecologic oncology. 156(1)
Objective This phase 1b/2 clinical trial (NCT01663857) evaluated the efficacy of ralimetinib in combination with gemcitabine (G) and carboplatin (C), followed by maintenance ralimetinib, for patients with recurrent platinum-sensitive epithelial ovari
Publikováno v:
Journal of Public Health Management and Practice. 22:466-471
CONTEXT Adult colorectal cancer screening (CRCS) can lower disease incidence and mortality. However, widespread implementation is inconsistent, especially in the public sector. While specific interventions to increase CRCS have been identified, first
Autor:
Suzanne F. Jones, Ji Lin, Howard A. Burris, Ly M. Nguyen, Lisa Golden, Aimee Bence Lin, David S. Hong, Johanna C. Bendell, Todd M. Bauer, Aung Naing, Razelle Kurzrock, Filip Janku, Jeffrey R. Infante, Sarina Anne Piha-Paul, Faye M. Johnson, Scott M. Hynes
Publikováno v:
Journal of Clinical Oncology. 34:1764-1771
Purpose The primary objective was to determine safety, toxicity, and a recommended phase II dose regimen of LY2606368, an inhibitor of checkpoint kinase 1, as monotherapy. Patients and Methods This phase I, nonrandomized, open-label, dose-escalation
Autor:
Katherine M Bell-McGuinn, Jalid Sehouli, Daphne L. Farrington, Kathleen N. Moore, Matthew A. Powell, Paul Buderath, Florian Heitz, Ignace Vergote, Wei Zhang, Lisa Golden, Anne Hamilton, Christine Lee, James Fiorica, Robert M. Wenham, Celine Pitou, Michael Teneriello
Publikováno v:
Journal of Clinical Oncology. 37:5537-5537
5537 Background: p38 mitogen-activated protein kinase (MAPK) regulates cytokine production in the tumor microenvironment and enables therapeutic resistance of cancer cells. Ralimetinib (R) is a selective small-molecule inhibitor of p38α and p38β MA